StocksMedium•6 November 2026•
1 min read
MannKind Forecasts $1B Revenue from United Therapeutics Partnership
Key Facts
1MannKind anticipates $1B in revenue from its deal with United Therapeutics between 2027 and 2030.
2MannKind is targeting profitability in the fourth quarter of 2026.
MannKind anticipates generating $1 billion in revenue from its deal with United Therapeutics between 2027 and 2030. Seeking Alpha reported that the company is also targeting profitability in the fourth quarter of 2026, supported by the expected scaling of royalty and manufacturing revenue streams.
MannKind closed at $3.76 on November 5, 2026, while United Therapeutics closed at $565.72 on the same date. The long-term revenue guidance reflects the ongoing collaboration between the two firms within the biotechnology sector.